Table 2 Demographic data of the patients with partial response and failure to sodium channel blocking antiseizure medications
|  | All (n = 91) | Partial response (n = 23) | Failure (n = 68) | p |
|---|---|---|---|---|
Onset age (year) | 12.8 (4.5–20.0) | 11.0 (3.0–19.5) | 13 (6.0–20.0) | 0.496 |
Male | 46 (50.5) | 11 (47.8) | 35 (51.5) | reference |
Female | 45 (49.5) | 12 (52.2) | 33 (48.5) | 0.476 |
Seizure type | ||||
 Focal | 59 (64.8) | 14 (60.9) | 45 (66.2) | 0.811 |
 Generalized | 27 (29.7) | 8 (34.8) | 19 (27.9) |  |
 Unspecified | 5 (5.5) | 1 (4.3) | 4 (5.9) |  |
Etiology | ||||
 Structural | 21 (23.1) | 5 (21.7) | 16 (23.5) | 0.659 |
 CNS infection | 6 (6.6) | 2 (8.7) | 4 (5.9) |  |
 Genetic | 3 (3.3) | 0 (0.0) | 3 (4.4) |  |
 Autoimmune | 3 (3.3) | 0 0.0) | 3 (4.4) |  |
 Unknown | 58 (63.7) | 16 (69.6) | 42 (61.8) |  |
Number of ASMs | ||||
 1 | 7 (7.7) | 1 (4.3) | 6 (8.8) |  |
 2 | 24 (26.4) | 6 (26.1) | 18 (26.5) |  |
 3 | 35 (38.5) | 10 (43.5) | 25 (36.8) |  |
 4 | 14 (15.4) | 5 (21.7) | 9 (13.2) |  |
 5 | 9 (9.9) | 1 (4.3) | 8 (11.8) |  |
 6 | 2 (2.2) | 0 (0.0) | 2 (2.9) |  |
Concurrent ASMs | ||||
 Carbamazepine | 23 | 5 | 18 |  |
 Clobazam | 9 | 1 | 8 |  |
 Gabapentin | 2 | 0 | 2 |  |
 Lacosamide | 3 | 1 | 2 |  |
 Lamotrigine | 35 | 9 | 26 |  |
 Levetiracetam | 54 | 13 | 41 |  |
 Oxcarbazepine | 15 | 7 | 8 |  |
 Perampanel | 11 | 1 | 10 |  |
 Phenobarbital | 12 | 2 | 10 |  |
 Phenytoin | 18 | 4 | 14 |  |
 Pregabalin | 3 | 0 | 3 |  |
 Topiramate | 28 | 11 | 17 |  |
 Valproic acid | 32 | 8 | 24 |  |
 Vigabatrin | 4 | 1 | 3 |  |
 Zonisamide | 24 | 5 | 19 |  |